A previous preclinical study found that induced expression of the heregulin gene worsened the sensitivity to the EGFR-TKI erlotinib of an NSCLC cell line harboring an EGFR-activating mutation27. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.